Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Binding of High Mobility Group A proteins to the mammalian genome occurs as a function of AT-content [ChIP-Seq]

ABSTRACT: High mobility group (HMG) proteins are of similar size as histones with HMGA1 and HMGA2 being particularly abundant in replicating normal tissues and in cancerous cells. While numerous roles for HMGA proteins have been proposed we lack a comprehensive description of their genomic location as a function of chromatin, DNA sequence and functional domains. Here we report such a characterization of HMGA proteins in mouse embryonic stem cells in which we introduce biotin-tagged constructs of wild-type and DNA binding domain mutants. Comparative analysis of their genome-wide distribution reveals pervasive binding, a feature that critically depends on a functional DNA binding domain and which is shared by both HMGA proteins. Assessment of the underlying queues instructive for this binding modality identifies AT richness as the major criteria for local binding. Additionally, we show that other chromatin states such as those linked to cis-regulatory regions have little impact on HMGA binding both in stem and differentiated cells. As a consequence HMGA proteins are found most enriched at regions of higher AT density such as constitutively heterochromatic regions but are absent from enhancers and promoters arguing for a limited role in regulating individual genes. In line with this model we show that genetic deletion of HMGA proteins in stem cells causes limited transcriptional effects and that binding is conserved in neuronal progenitors.

ORGANISM(S): Mus musculus

PROVIDER: GSE100405 | GEO | 2017/12/21

SECONDARY ACCESSION(S): PRJNA391576

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Binding of High Mobility Group A proteins to the mammalian genome occurs as a function of AT-content [RNA-Seq]

Project description:High mobility group (HMG) proteins are of similar size as histones with HMGA1 and HMGA2 being particularly abundant in replicating normal tissues and in cancerous cells. While numerous roles for HMGA proteins have been proposed we lack a comprehensive description of their genomic location as a function of chromatin, DNA sequence and functional domains. Here we report such a characterization of HMGA proteins in mouse embryonic stem cells in which we introduce biotin-tagged constructs of wild-type and DNA binding domain mutants. Comparative analysis of their genome-wide distribution reveals pervasive binding, a feature that critically depends on a functional DNA binding domain and which is shared by both HMGA proteins. Assessment of the underlying queues instructive for this binding modality identifies AT richness as the major criteria for local binding. Additionally, we show that other chromatin states such as those linked to cis-regulatory regions have little impact on HMGA binding both in stem and differentiated cells. As a consequence HMGA proteins are found most enriched at regions of higher AT density such as constitutively heterochromatic regions but are absent from enhancers and promoters arguing for a limited role in regulating individual genes. In line with this model we show that genetic deletion of HMGA proteins in stem cells causes limited transcriptional effects and that binding is conserved in neuronal progenitors.

2017-12-21 | GSE100406 | GEO

HMGA1: A master regulator of tumor progression in triple-negative breast cancer cells

Project description:Emerging evidence suggests that tumor cells metastasize by co-opting stem cell transcriptional networks, although the molecular underpinnings of this process are poorly understood. Here, we show for the first time that the high mobility group A1 (HMGA1) gene drives metastatic progression in triple negative breast cancer cells (MDA-MB-231) by reprogramming cancer cells to a stem-like state. We discovered an HMGA1 signature in triple negative breast cancer cells that is highly enriched in embryonic stem cells. Together, these findings indicate that HMGA1 is a master regulator of tumor progression in breast cancer by reprogramming cancer cells through stem cell transcriptional networks. Future studies are needed to determine how to target HMGA1 in therapy. HMGA1 was knocked-down in MDA-MB-231 cells using siRNA as we previously described (Tesfaye A 2007). RNA from three independent knockdown experiements along with 3 control populations were collected by Rneasy miniprep (Qiagen) and analyzed by Affymetrix Human Exon 1.0 ST platform.

2015-02-18 | E-GEOD-45483 | biostudies-arrayexpress

HMGA1: A master regulator of tumor progression in triple-negative breast cancer cells

2015-02-18 | GSE45483 | GEO

LEDGF and HDGF2, histone H3K36 methyl-binding proteins that assist RNA polymerase II transcription through nucleosomes

Project description:FACT (facilitates chromatin transcription) is a protein complex that allows RNAPII to overcome the nucleosome-induced barrier to transcription. While abundant in stem cells and many cancer cells, FACT it is not very abundant in most tissues. Therefore, we screened for additional factors that might replace FACT in such tissues. Here we report the identification of two such proteins, LEDGF and HDGF2, each containing two HMGA-like AT-hooks and a PWWP methyl-lysine reading domain known to bind to H3K36me2 and H3K36me3. LEDGF and HDGF2 localize with H3K36me2/3 at genomic regions containing active genes, usually adjacent to H3K27me3 domains. In myoblasts, where FACT expression is low, LEDGF and HDGF2 are enriched on most active genes. Upon differentiation to myotubes, HDGF2 is recruited to the majority of myotube up-regulated genes and is required for their expression. We propose that LEDGF and HDGF2 substitute for FACT in differentiated tissues and that their distribution on the genome helps maintain transcriptional programs unique to particular cell types.

2019-09-01 | GSE117155 | GEO

Methylation-dependent and -independent genomic targeting principles of the MBD protein family

Project description:In order to gain insight into DNA methylation readout, we have established a controlled strategy for profiling genomic targeting of chromatin-interacting factors in vivo. With this approach we determined binding preferences for the methyl-CpG binding domain (MBD) family of proteins, including disease relevant mutants, deletions and isoforms. In vivo binding of MBD proteins occurs as a linear function of local methylation density, and is dependent on functional MBD domain M-bM-^@M-^S methyl-CpG interactions. This directs specificity of MBD proteins to methylated, CpG dense and inactive regulatory regions. In contrast, binding to unmethylated sites is MBD protein specific and mediated via alternative domains or protein-protein interactions. The latter is observed for NuRD complex-mediated MBD2 tethering to a subset of unmethylated, tissue-specific regulatory regions, similar to MBD3. These functional binding maps reveal methylation-dependent and -independent binding modes determined by distinct protein domains and revise current models of DNA methylation readout through MBD proteins. Comparative binding analysis for the MBD family of proteins utilizing recombinase-assisted mapping of biotin-tagged proteins (RAMBiO). This set contains maps for 29 samples including wild type MBD proteins, mutants and domain variants in mouse ES cells, derived neurons (NP and TN) and Dnmt1/3a/3b triple-KO ES cells (TKO).

2013-04-01 | E-GEOD-39610 | biostudies-arrayexpress

ACD15, ACD21 and SLN regulate accumulation and mobility of MBD6 to silence genes and transposable elements [ChIP-seq]

Project description:DNA methylation mediates silencing of transposable elements and genes in part via recruitment of the Arabidopsis MBD5/6 complex, which contains the methyl-CpG-binding domain (MBD) proteins MBD5 and MBD6, and the J-domain containing protein SILENZIO (SLN). Here we characterize two additional complex members: α-crystalline domain containing proteins ACD15 and ACD21. We show that they are necessary for gene silencing, bridge SLN to the complex, and promote higher order multimerization of MBD5/6 complexes within heterochromatin. These complexes are also highly dynamic, with the mobility of complex components regulated by the activity of SLN. Using a dCas9 system, we demonstrate that tethering the ACDs to an ectopic site outside of heterochromatin can drive massive accumulation of MBD5/6 complexes into large nuclear bodies. These results demonstrate that ACD15 and ACD21 are critical components of gene silencing complexes that act to drive the formation of higher order, dynamic assemblies.

2023-09-14 | GSE234531 | GEO

ACD15, ACD21 and SLN regulate accumulation and mobility of MBD6 to silence genes and transposable elements [RNA-seq]

2023-09-14 | GSE234530 | GEO

HMGA1 Chromatin Regulators Drive MPN Progression [scRNA-Seq]

Project description:Myeloproliferative neoplasms (MPN) transform to myelofibrosis (MF) and highly lethal acute myeloid leukemia (AML), although actionable mechanisms driving progression remain elusive. The HMGA1 chromatin regulator is up-regulated during MPN progression with highest levels after transformation. HMGA1 depletion in JAK2V617F MPN AML cell lines disrupts proliferation, clonogenicity, and leukemic engraftment. Surprisingly, loss of just a single Hmga1 allele prevents progression to MF in JAK2V617F transgenic mice, decreasing blood counts and expansion in stem and myeloid progenitors while preventing splenomegaly and fibrosis within the spleen and bone marrow. RNA sequencing revealed HMGA1-dependent transcriptional networks that govern proliferation (E2F, G2M, mitosis, MYC targets) and cell fate, including the GATA2 master regulatory gene. Silencing GATA2 recapitulates phenotypes observed with HMGA1 depletion whereas GATA2 re-expression partially rescues leukemogenesis. HMGA1 transactivates GATA2 through sequences near the developmental enhancer (+9.5), increasing chromatin accessibility and recruiting active histone marks. Further, HMGA1 transcriptional networks, including GATA2, are activated in human MF after leukemic transformation. Further, HMGA1 depletion synergizes with the JAK2 inhibitor, ruxolitinib, to prolong survival in murine MPN AML. These findings illuminate HMGA1 as a key epigenetic switch required for MPN transformation and promising therapeutic target to treat or prevent disease progression.

2023-10-05 | GSE197942 | GEO

HMGA1 Chromatin Regulators Drive MPN Progression [ChIP-Seq]

2023-10-05 | GSE189569 | GEO

HMGA1 Chromatin Regulators Drive MPN Progression [ATAC-Seq]

2023-10-05 | GSE189568 | GEO